MDFI is a novel biomarker for poor prognosis in LUAD

MDFI is a novel biomarker for poor prognosis in LUAD

BackgroundApproximately 80% of lung cancers are non-small cell lung cancers (NSCLC). Lung adenocarcinoma (LUAD) is the main subtype of NSCLC. The incidence and mortality of lung cancer are also increasing yearly. Myogenic differentiation family inhibitor (MDFI) as a transcription factor, its role in...

Full description

Bibliographic Details
Main Authors: Pengyu Chen, Zhen Quan, Xueyu Song, Zhaojia Gao, Kai Yuan
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-10-01
Series:Frontiers in Oncology
Subjects:
MDFI
LUAD
TCGA
high expression
prognosis
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.1005962/full

Similar Items

Similar Items